Short Interest in Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Expands By 130.8%

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 4,921 shares, a growth of 130.8% from the April 15th total of 2,132 shares. Based on an average daily volume of 2,702 shares, the days-to-cover ratio is currently 1.8 days. Currently, 2.6% of the shares of the stock are short sold.

Bitwise MARA Option Income Strategy ETF Stock Down 4.3%

Shares of IMRA stock traded down $0.75 on Friday, reaching $16.59. 2,855 shares of the stock were exchanged, compared to its average volume of 5,498. Bitwise MARA Option Income Strategy ETF has a 1-year low of $11.99 and a 1-year high of $60.73. The stock has a market cap of $3.15 million, a P/E ratio of 331.80 and a beta of 3.28. The firm has a 50 day moving average of $14.70 and a two-hundred day moving average of $17.15.

Insider Activity at Bitwise MARA Option Income Strategy ETF

In related news, insider Helen Louise Collins sold 5,000 shares of the stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $47.67, for a total transaction of $238,350.00. Following the transaction, the insider directly owned 25,000 shares in the company, valued at approximately $1,191,750. This represents a 16.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 50,000 shares of company stock worth $1,781,150 in the last ninety days. Insiders own 37.30% of the company’s stock.

About Bitwise MARA Option Income Strategy ETF

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.